Literature DB >> 25497960

Analysis of a compartmental model of amyloid beta production, irreversible loss and exchange in humans.

Donald L Elbert1, Bruce W Patterson2, Randall J Bateman3.   

Abstract

Amyloid beta (Aβ) peptides, and in particular Aβ42, are found in senile plaques associated with Alzheimer's disease. A compartmental model of Aβ production, exchange and irreversible loss was recently developed to explain the kinetics of isotope-labeling of Aβ peptides collected in cerebrospinal fluid (CSF) following infusion of stable isotope-labeled leucine in humans. The compartmental model allowed calculation of the rates of production, irreversible loss (or turnover) and short-term exchange of Aβ peptides. Exchange of Aβ42 was particularly pronounced in amyloid plaque-bearing participants. In the current work, we describe in much greater detail the characteristics of the compartmental model to two distinct audiences: physician-scientists and biokineticists. For physician-scientists, we describe through examples the types of questions the model can and cannot answer, as well as correct some misunderstandings of previous kinetic analyses applied to this type of isotope labeling data. For biokineticists, we perform a system identifiability analysis and a sensitivity analysis of the kinetic model to explore the global and local properties of the model. Combined, these analyses motivate simplifications from a more comprehensive physiological model to the final model that was previously presented. The analyses clearly demonstrate that the current dataset and compartmental model allow determination with confidence a single 'turnover' parameter, a single 'exchange' parameter and a single 'delay' parameter. When combined with CSF concentration data for the Aβ peptides, production rates may also be obtained.
Copyright © 2015 Elsevier Inc. All rights reserved.

Entities:  

Keywords:  Alzheimer's disease; Amyloid beta; Compartmental model; Identifiability; Kinetics; Sensitivity analysis

Mesh:

Substances:

Year:  2014        PMID: 25497960      PMCID: PMC4323682          DOI: 10.1016/j.mbs.2014.11.004

Source DB:  PubMed          Journal:  Math Biosci        ISSN: 0025-5564            Impact factor:   2.144


  19 in total

1.  The design and analysis of isotope experiments.

Authors:  D B ZILVERSMIT
Journal:  Am J Med       Date:  1960-11       Impact factor: 4.965

2.  Interpreting the aggregation kinetics of amyloid peptides.

Authors:  Riccardo Pellarin; Amedeo Caflisch
Journal:  J Mol Biol       Date:  2006-06-05       Impact factor: 5.469

3.  Human amyloid-beta synthesis and clearance rates as measured in cerebrospinal fluid in vivo.

Authors:  Randall J Bateman; Ling Y Munsell; John C Morris; Robert Swarm; Kevin E Yarasheski; David M Holtzman
Journal:  Nat Med       Date:  2006-06-25       Impact factor: 53.440

Review 4.  Use of stable isotopically labeled tracers for studies of metabolic kinetics: an overview.

Authors:  B W Patterson
Journal:  Metabolism       Date:  1997-03       Impact factor: 8.694

5.  Parameter and structural identifiability concepts and ambiguities: a critical review and analysis.

Authors:  C Cobelli; J J DiStefano
Journal:  Am J Physiol       Date:  1980-07

Review 6.  The amyloid hypothesis of Alzheimer's disease: progress and problems on the road to therapeutics.

Authors:  John Hardy; Dennis J Selkoe
Journal:  Science       Date:  2002-07-19       Impact factor: 47.728

7.  Abeta43 is more frequent than Abeta40 in amyloid plaque cores from Alzheimer disease brains.

Authors:  Hedvig Welander; Jenny Frånberg; Caroline Graff; Erik Sundström; Bengt Winblad; Lars O Tjernberg
Journal:  J Neurochem       Date:  2009-05-15       Impact factor: 5.372

8.  Increased in vivo amyloid-β42 production, exchange, and loss in presenilin mutation carriers.

Authors:  Rachel Potter; Bruce W Patterson; Donald L Elbert; Vitaliy Ovod; Tom Kasten; Wendy Sigurdson; Kwasi Mawuenyega; Tyler Blazey; Alison Goate; Robert Chott; Kevin E Yarasheski; David M Holtzman; John C Morris; Tammie L S Benzinger; Randall J Bateman
Journal:  Sci Transl Med       Date:  2013-06-12       Impact factor: 17.956

Review 9.  Take five--BACE and the gamma-secretase quartet conduct Alzheimer's amyloid beta-peptide generation.

Authors:  Christian Haass
Journal:  EMBO J       Date:  2004-01-29       Impact factor: 11.598

10.  Amyloid beta -protein (Abeta) assembly: Abeta 40 and Abeta 42 oligomerize through distinct pathways.

Authors:  Gal Bitan; Marina D Kirkitadze; Aleksey Lomakin; Sabrina S Vollers; George B Benedek; David B Teplow
Journal:  Proc Natl Acad Sci U S A       Date:  2002-12-27       Impact factor: 11.205

View more
  8 in total

1.  Age and amyloid effects on human central nervous system amyloid-beta kinetics.

Authors:  Bruce W Patterson; Donald L Elbert; Kwasi G Mawuenyega; Tom Kasten; Vitaliy Ovod; Shengmei Ma; Chengjie Xiong; Robert Chott; Kevin Yarasheski; Wendy Sigurdson; Lily Zhang; Alison Goate; Tammie Benzinger; John C Morris; David Holtzman; Randall J Bateman
Journal:  Ann Neurol       Date:  2015-07-20       Impact factor: 10.422

2.  Effect of sleep on overnight cerebrospinal fluid amyloid β kinetics.

Authors:  Brendan P Lucey; Terry J Hicks; Jennifer S McLeland; Cristina D Toedebusch; Jill Boyd; Donald L Elbert; Bruce W Patterson; Jack Baty; John C Morris; Vitaliy Ovod; Kwasi G Mawuenyega; Randall J Bateman
Journal:  Ann Neurol       Date:  2018-01       Impact factor: 10.422

3.  Associations Between β-Amyloid Kinetics and the β-Amyloid Diurnal Pattern in the Central Nervous System.

Authors:  Brendan P Lucey; Kwasi G Mawuenyega; Bruce W Patterson; Donald L Elbert; Vitaliy Ovod; Tom Kasten; John C Morris; Randall J Bateman
Journal:  JAMA Neurol       Date:  2017-02-01       Impact factor: 18.302

4.  Semimechanistic Population Pharmacokinetic Modeling to Investigate Amyloid Beta Trafficking and Accumulation at the BBB Endothelium.

Authors:  Zengtao Wang; Nidhi Sharda; Geoffry L Curran; Ling Li; Val J Lowe; Karunya K Kandimalla
Journal:  Mol Pharm       Date:  2021-10-19       Impact factor: 5.364

Review 5.  Alzheimer's disease: A matter of blood-brain barrier dysfunction?

Authors:  Axel Montagne; Zhen Zhao; Berislav V Zlokovic
Journal:  J Exp Med       Date:  2017-10-23       Impact factor: 14.307

6.  A Translational Systems Pharmacology Model for Aβ Kinetics in Mouse, Monkey, and Human.

Authors:  T Karelina; O Demin; T Nicholas; Y Lu; S Duvvuri; H A Barton
Journal:  CPT Pharmacometrics Syst Pharmacol       Date:  2017-08-10

7.  Aβ34 is a BACE1-derived degradation intermediate associated with amyloid clearance and Alzheimer's disease progression.

Authors:  Filip Liebsch; Luka Kulic; Charlotte Teunissen; Adeola Shobo; Irem Ulku; Vivienne Engelschalt; Mark A Hancock; Wiesje M van der Flier; Peter Kunach; Pedro Rosa-Neto; Philip Scheltens; Judes Poirier; Paul Saftig; Randall J Bateman; John Breitner; Christoph Hock; Gerhard Multhaup
Journal:  Nat Commun       Date:  2019-05-20       Impact factor: 14.919

8.  Importance of CSF-based Aβ clearance with age in humans increases with declining efficacy of blood-brain barrier/proteolytic pathways.

Authors:  Donald L Elbert; Bruce W Patterson; Brendan P Lucey; Tammie L S Benzinger; Randall J Bateman
Journal:  Commun Biol       Date:  2022-01-27
  8 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.